rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MOLN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
      Nov 5Yahoo FinanceMOLN
      Molecular Partners stock rating reiterated at Buy by H.C. Wainwright
      Nov 2Investing.comMOLN
      Swiss biotech firm Molecular Partners to cut nearly half of workforce
      Oct 29ReutersMOLN
      Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
      Oct 29Yahoo FinanceMOLN
      Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base

      Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.

      Aug 26The Globe and MailMOLN
      Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

      DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in 2027Cash position of CHF 67.9 million (USD ~84 million) as of June 30, 2026, expected to fund operations into late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) --

      Aug 25Yahoo FinanceMOLN

      This is the newest page. Registered accounts read further back.